BioCardia has completed consultations with Japan's PMDA on the application materials for its CardiAMP Cell Therapy System, a treatment for ischemic heart failure. This step moves the company closer to regulatory approval and potential commercialization in Japan, a key market for cardiovascular therapies. CardiAMP offers a minimally invasive, catheter-based cell therapy option for patients with unmet medical needs. BioCardia aims to start treating patients and generating commercial revenue in Japan by 2028, pending final PMDA review and approval.
BioCardia's progress with Japan's PMDA on CardiAMP Cell Therapy System is noted here with Pluang's health sector data as of Nov 06, 2026 19:41 WIB: Of 150 priced health-sector US stocks, 52 rose and 90 fell. Notable movers include Smith & Nephew plc (SNN) at USD 30.70 with a -4.09% change and a typical hold time of 123 days, 10X Genomics Inc (TXG) at USD 55.80 down -3.89% with 88% sell order activity, and Heron Therapeutics Inc (HRTX) at USD 0.29 up 3.54% with 76% buy order activity. The most notable figure is the 88% sell order activity on TXG.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
